Shanghai Henlius Biotech has celebrated winning Chinese approval for a key rheumatoid arthritis indication for its groundbreaking rituximab biosimilar. The approval offers Henlius access to a wider patient population for the product, allowing the firm to pursue a “differentiated strategy” for the Rituxan rival.
Henlius Wins Chinese Approval For Rituximab RA Indication
Wider Potential Patient Population Allows Firm ‘Differentiated Strategy’
Henlius says it can now pursue a “differentiated strategy” for its HLX01 rituximab biosimilar in China, after winning approval for a key rheumatoid arthritis indication from the NMPA.
More from Biosimilars
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.